Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — JP Morgan Healthcare Conference 2011

32 slides from Questcor Pharmaceuticals's conference presentation, Jan 10, 2011

  1. Slide 1: Exhibit 99.2

    Slide 1: Exhibit 99.2

    Exhibit 99.2

  2. Slide 2: JP Morgan Healthcare Conference, January 2011

    Slide 2: JP Morgan Healthcare Conference, January 2011

    JANUARY 2011 JP Morgan Healthcare NASDAQ: QCOR C O N F E R E N C E JANUARY 2011 JP Morgan Healthcare NASDAQ: QCOR C O N F E R E N C E

  3. Slide 3: Safe Harbor Statement

    Slide 3: Safe Harbor Statement

    3 Safe Harbor Statement Note: Except for the historical information contained herein, this presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual resu

  4. Slide 4: Questcor Overview

    Slide 4: Questcor Overview

    4 Questcor Overview A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions

  5. Slide 5: Questcor Overview

    Slide 5: Questcor Overview

    5 Questcor Overview Flagship Product: • Profitable, cash flow positive, $115M in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Infantile Spasms, Nephrotic Syndrome • Combined markets opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market Fina

  6. Slide 6: History of Acthar

    Slide 6: History of Acthar

    6 History of Acthar 1950 2000 2010 1952 First Approved 1968-1973 DESI Review Label Expands 1950 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010

  7. Slide 7: Significant Barriers to Entry

    Slide 7: Significant Barriers to Entry

    7 Significant Barriers to Entry

  8. Slide 8: Questcor Growth Engine

    Slide 8: Questcor Growth Engine

    8 Questcor Growth Engine Multiple Sclerosis Infantile Spasms Nephrotic Syndrome Multiple Sclerosis Infantile Spasms Nephrotic Syndrome

  9. Slide 9: Large Market Opportunity

    Slide 9: Large Market Opportunity

    9 Large Market Opportunity *Represents estimated net sales market opportunity based on internal company estimates ** Represents approximate current net sales annualized run rate based on internal company estimates

  10. Slide 10: Multiple Sclerosis: $500M to $2B+ Potential Market

    Slide 10: Multiple Sclerosis: $500M to $2B+ Potential Market

    10 Multiple Sclerosis $500M to $2B+ Potential Market *Data on this slide is based on US only. Based on internal company estimates. $500M to $2B+ $500M to $2B+ Potential Market Potential Market

  11. Slide 11: Acthar and MS

    Slide 11: Acthar and MS

    11 Acthar and MS Acthar when “Steroids are not suitable” • Acute treatment • Treatment for 1-2 weeks (based on prescription data) • $40K-$50K/Rx Acthar when “Steroids are not suitable”

  12. Slide 12: MS Trends

    Slide 12: MS Trends

    12 • Q4-2010 results – Q4-10 new paid Rxs up 66% vs. Q409 – MS sales over 50% of QCOR sales – Over $65M annualized run rate – Approximately one in six Rxs is a repeat patient • Growing number of Acthar prescribers – But only <400 out of 8,000 neurologists • Speakers bureau growing MS Trends • Q4-201

  13. Slide 13: MS Sales - Record of Consistent Growth

    Slide 13: MS Sales - Record of Consistent Growth

    13 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which

  14. Slide 14: MS Sales Calls vs. New Paid Rxs

    Slide 14: MS Sales Calls vs. New Paid Rxs

    14 MS Sales Calls vs. New Paid Rxs *MS call data approximate

  15. Slide 15: Sales Force Expansion

    Slide 15: Sales Force Expansion

    15 • Doubled sales force: hiring/training Aug-Oct 2010 (38 to 77 sales reps) • Newly expanded sales force began call activity Nov 1 – Significant increase in MS-treating neurologists targeted for sales calls – Now also targeting child neurologists for sales calls Sales Force Expansion • Doubled sale

  16. Slide 16: Infantile Spasms

    Slide 16: Infantile Spasms

    16 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by

  17. Slide 17: Acthar and IS

    Slide 17: Acthar and IS

    17 • Used by over half of child neurologists • FDA approval 10/15/10 – 7 year orphan exclusivity for IS indication • Crisis therapy • Treatment for 2-4 weeks (based on prescription data) – In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no

  18. Slide 18: IS Sales Plan

    Slide 18: IS Sales Plan

    18 • Significant quarterly variability • Q4-2010 sales within historic range • Promotion effort began 11/1/10 • Potential to increase IS revenue – Acthar currently used to treat 30-50% of IS patients IS Sales Plan • Significant quarterly variability • Q4-2010 sales within historic range • Promotion

  19. Slide 19: Nephrotic Syndrome

    Slide 19: Nephrotic Syndrome

    19 • Characterized by excessive spilling of protein from the kidney into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options Nephrotic Syndrome • Characterized by excessive spilling of protein from the kidney i

  20. Slide 20: Acthar and NS

    Slide 20: Acthar and NS

    20 • Single application treatment for reduction of proteinuria in: – Membranous nephropathy (on-label) – Lupus nephritis (on-label) – Focal segmental glomerular sclerosis (FSGS) (on-label) – Diabetic nephropathy (not on-label) • Treatment for 4-6 months (based on prescription data) • $150K-250K/Rx A

  21. Slide 21: Proof of Concept Data

    Slide 21: Proof of Concept Data

    21 • Available November 2010 • Case series showed response from Acthar for refractory idiopathic membranous nephropathy (on-label) – 9 of 11 patients met response criteria • Positive signal received in diabetic nephropathy trial (not on-label) – 9 of 15 patients on Acthar met response criteria and n

  22. Slide 22: R&D Effort in NS

    Slide 22: R&D Effort in NS

    22 • Dose ranging trial for idiopathic membranous nephropathy – $5-7M multi-center trial, n=100 – Reduction of proteinuria is endpoint • Presently designing a study in collaboration with FDA for diabetic nephropathy – Dose ranging trial – If successful, Phase III trial would follow R&D Effort in NS

  23. Slide 23: NS Business Plan

    Slide 23: NS Business Plan

    23 • Nov 2010 ASN meeting – First meeting with commercial team presence – Data presented via podium/posters – 30+ doctor advisory board meeting • Hired/hiring 5 reps to sell Acthar to nephrologists – Develop selling process and generate sales – Expand sales force if sales increase NS Business Plan •

  24. Slide 24: Immediate Acthar Growth Opportunities

    Slide 24: Immediate Acthar Growth Opportunities

    24 • MS - Build on sales momentum, lots of market headroom • IS - Incremental market share growth • NS - Establish Acthar as a therapeutic alternative in this sizeable market Immediate Acthar Growth Opportunities *Represents estimated net sales market opportunity based on internal company estimates

  25. Slide 25: Financials

    Slide 25: Financials

    25 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive

  26. Slide 26: Quarterly Results - Q3 2010

    Slide 26: Quarterly Results - Q3 2010

    26 Quarterly Results - Q3 2010 Net Sales ($M) Gross Margin Operating Inc ($M) EPS $31.3 93% $16.8 $0.18 $13.9 86% $1.8 $0.02 Q3 - 2010 Q3 - 2009 Record Sales and Solid Earnings Net Sales ($M) Gross Margin Operating Inc ($M) EPS $31.3 93% $16.8 $0.18 $13.9 86% $1.8 $0.02 Q3 - 2010 Q3 - 2009 Record Sa

  27. Slide 27: Preliminary Q4 Information

    Slide 27: Preliminary Q4 Information

    27 Up several million $ vs Q3-10 Up 66% vs Q409 Within historic range Promotion effort starting now 91 new/paid IS Rxs Preliminary Q4 Information 353 new/paid MS Rxs 7 new/paid NS Rxs Expenses Up several million $ vs Q3-10 Up 66% vs Q409 Within historic range Promotion effort starting now 91 new/pai

  28. Slide 28: Questcor is Cash Flow Positive

    Slide 28: Questcor is Cash Flow Positive

    28 Questcor is Cash Flow Positive Debt-free balance sheet Cash / ST Investment Accounts Receivable $115m* $11m 12/31/10 Debt-free balance sheet *After return of $67 million of cash to shareholders through share repurchases. Cash / ST Investment Accounts Receivable $115m* $11m 12/31/10

  29. Slide 29: Go Forward Plan - Sell More Acthar

    Slide 29: Go Forward Plan - Sell More Acthar

    29 • Expanded sales force to pursue MS/IS • Dedicated pilot NS sales team starting January 2010 • Develop other markets for Acthar – Acthar is its own pipeline with 15 other on-label and many possible other therapeutic uses – Further defining and developing the unique characteristics of Acthar • No

  30. Slide 30: Investment Highlights

    Slide 30: Investment Highlights

    30 • Questcor is streamlined, focused & profitable • Acthar has sustainable competitive advantages • Focus on substantial growth in MS sales • Recent IS approval/label modernization • Significant upside with NS • Market sizes have good growth potential • Cash flow positive/no debt Investment Highlig

  31. Slide 31: January

    Slide 31: January

    NASDAQ: QCOR J A N U A R Y 2 0 1 1 NASDAQ: QCOR J A N U A R Y 2 0 1 1

  32. Slide 32: Questcor

    Slide 32: Questcor

    (§ QUESTCOR

Source: SEC EDGAR · 8-K filed Jan 10, 2011

More decks from Questcor Pharmaceuticals Inc